This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q63592379
rdf:type
wikibase:Item
schema:description
clinical trial клінічне випробування ensayu clínicu klinisch onderzoek
rdfs:label
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
skos:prefLabel
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
schema:name
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
p:P1476
wds:Q63592379-8A609F43-298C-4847-868D-95057C925E9A
wdt:P1476
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose, Induction Study to Evaluate the Safety, Tolerability and Optimal Dose of ABX464 Compared With Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Have Inadequate Response, Loss of Response, or Intolerance With at Least One of the Following Agents: Immunosuppressant Treatment (i.e. Azathioprine, 6-mercaptopurine, Methotrexate), Tumor Necrosis Factor Alpha [TNF-α] Inhibitors, Vedolizumab, JAK Inhibitors and/or Corticosteroid Treatment
p:P582
wds:Q63592379-D9A11BA1-9996-4165-9B91-A96F89B2A278
wdt:P582
2020-06-30T00:00:00Z
p:P31
wds:Q63592379-D39AE9F0-87D2-4B2A-B040-D57C5D78A80F
wdt:P31
wd:Q30612
p:P580
wds:Q63592379-441C22A8-01B4-4094-BCC2-60D0C22F5A46
wdt:P580
2019-01-20T00:00:00Z
p:P6153
wds:Q63592379-77A13699-336D-4FF5-8BC7-A9FAA86CE052 wds:Q63592379-2EB94740-E544-4F16-B49C-AE5C124DCCD2 wds:Q63592379-3232B62D-678F-4598-9E7A-0CC934BC9997 wds:Q63592379-ED4001A7-8B73-4DFA-A812-1A61B0EC1C0E wds:Q63592379-F208E588-17E3-4905-B64E-93FE8A95F865 wds:Q63592379-F4A2171E-4AAD-4432-8207-2D93F58B493E wds:Q63592379-E2348866-4B8A-4576-88E6-03640BD0B0A9 wds:Q63592379-BCADA343-1EFA-4CFC-9D6F-05771BC268B2 wds:Q63592379-C0047929-FDF3-45FE-BE4C-88929427CEFA wds:Q63592379-C07DA6EB-A1F8-434D-93F2-89B1A53BF225 wds:Q63592379-CEC738AF-BC5A-4442-A6E0-94E967690EC0 wds:Q63592379-91BEE08B-97E6-439B-8D54-83FB97B89C0A
wdt:P6153
wd:Q13427644 wd:Q30280335 wd:Q1920549 wd:Q911561 wd:Q30280003 wd:Q170027 wd:Q30253940 wd:Q18745239 wd:Q1476505 wd:Q5902864 wd:Q3803602 wd:Q833670
p:P2899
wds:Q63592379-95B7650C-2120-4093-A423-91CA4B9D04EE
wdt:P2899
18
p:P1050
wds:Q63592379-FC7F83BF-2196-4F1D-8DE7-867D3011CAE4
wdt:P1050
wd:Q2453464
p:P1132
wds:Q63592379-94E2E388-B934-433F-9D49-C225471A0985
wdt:P1132
252
p:P4135
wds:Q63592379-E146970F-F8B4-4C5E-A9C5-F5439C2D030A
wdt:P4135
75
p:P8363
wds:Q63592379-B876C185-BD66-40CF-922C-7E8474C6241C
wdt:P8363
wd:Q78089383
p:P3098
wds:Q63592379-1A94D6D0-210E-423D-8E76-D71CCAD44D7D
wdt:P3098
NCT03760003
p:P6099
wds:Q63592379-4BF3383F-C9E3-4DFF-9170-CC1D319A6A65
wdt:P6099
wd:Q42824440